FOSINORM IN THE TREATMENT OF ESSENTIAL-HY PERTENSION WITH METABOLIC SYNDROME

The authors made an open non-comparative trial of fosinopril (fosinorm ) efficacy and tolerability in 20 patients (9 males and 11 females) wi th stage II mild and moderate essential hypertension accompanied with disturbed glucose tolerance and dislipidemia. Fosinorm was given in a dose 10-20 mg/day under 24-h monitoring of blood pressure. Diastolic p ressure returned to normal in 19(95%) patients, one patient showed a g ood hypotensive response. The mean 24-h fall in the systolic and diast olic pressure was significant and made up for systolic pressure 6.9% ( day-time 5.4%, night-time 6.2%), for diastolic pressure 7.5% (9.2% and 9.2%), respectively. Fosinorm had a minimal effect on carbohydrate me tabolism, total cholesterol, serum triglycerides. The conclusion is ma de that fosinorm is a highly effective antihypertensive drug positivel y influencing 24-h profile of blood pressure in the absence of negativ e action on carbohydrate and lipid metabolism.